LIVN News and Press, LivaNova PLC From 09/27/19

LivaNova PLC (NASDAQ:LIVN), a market-leading medical technology and innovation company, today announced the first patient enrolled in “A P r ospective, Multi-c e nter, Randomized C ontrolled Blinded Trial Dem o nstrating the Safety and Effectiveness of V NS Therapy ® System as ...

LivaNova PLC (NASDAQ:LIVN), a market-leading medical technology and innovation company, today announced it will present a summary of implantable neuromodulation technology for patients with heart failure during the 23rd Annual Scientific Meeting of the Heart Failure Society of America , Sept...

Study to evaluate VNS Therapy for Treatment-Resistant Depression in accordance with agency’s National Coverage Determination as part of its Coverage with Evidence Development Program LivaNova PLC (NASDAQ:LIVN), a market-leading medical technology and innovation company, today ...

LivaNova PLC (NASDAQ:LIVN), a market-leading medical technology and innovation company, today announced it will present two abstracts further establishing the viability of implantable neuromodulation technology to treat patients with heart failure during the European Society of Cardiology (E...

LivaNova PLC (LIVN) Q2 2019 Earnings Conference Call July 31, 2019, 08:00 ET Company Participants Matthew Dodds - SVP, Corporate Development Damien McDonald - CEO & Director Thad Huston - CFO Melissa Farina - VP, IR Conference Call Participants Frederick Wise - Stifel...

The following slide deck was published by LivaNova PLC in conjunction with their 2019 Q2 earnings Read more ...

LivaNova ( LIVN +1.6% ) Q2 results : Revenues: $277.2M (-3.6%); Cardiovascular: $172.2M (-2.4%); Neuromodulation: $104.3M (-5.8%); Other: $0.7M (+75.0%). More news on: LivaNova PLC, Healthcare stocks news, Earnings news and commentary, Read more ...

LivaNova PLC (NASDAQ: LIVN ): Q2 Non-GAAP EPS of $0.70 beats by $0.05 ; GAAP EPS of -$0.61. More news on: LivaNova PLC, Earnings news and commentary, Healthcare stocks news, Read more ...

LivaNova PLC (NASDAQ:LIVN), a market-leading medical technology and innovation company, today reported results for the quarter ended June 30, 2019. For the second quarter of 2019, worldwide sales from continuing operations were $277.2 million, a decrease of 3.6 percent on a reported basis...

CE Marked Bi-Flow is the only cannula designed to prevent leg ischemia during cardiac procedures requiring femoral artery cannulation LivaNova PLC (NASDAQ:LIVN), a market-leading medical technology company, today launched its innovative arterial femoral cannula, Bi-Flow, designed to p...